Muln stock forecast outlook is affected by short interest

Muln stock forecast outlook is affected by short interest nearing 12%, which could trigger a squeeze scenario if unexpected positive earnings are reported. Verastem (NASDAQ: VSTM ) is a biopharmaceutical company that is working on treatments for cancer. The company is focused specifically on RAS pathway-driven cancers and is developing treatments targeted toward mutated RAS genes. However, even with Canadian sales in the picture, the company is not expected to produce significant revenue for years, and investors face the dual headwinds of dwindling assets and rapidly rising share counts. Analysts revising muln stock forecast point to Q3 earnings as the decisive moment for investor confidence restoration in Mullen Automotive.